Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics

Nektar Therapeutics ($NKTR) announced an update on their ongoing clinical study. The Phase 3 study, officially titled “A Phase 3, Randomized, Doubl...

Nektar’s Phase 3 Eczema Trial Moves Forward: What Investors Should Watch

Analysts are intrested in these 5 stocks: ( ($KEEL) ), ( ($NKTR) ), ( ($INFQ) ), ( ($COIN) ) and ( ($ADSK) ). Here is a breakdown of their recent


Keel, Nektar, Infleqtion, Coinbase, Autodesk Trending With Analysts

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nek...

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

Nektar Therapeutics ($NKTR) announced an update on their ongoing clinical study. Nektar Therapeutics is running a Phase 3 study called “A Phase 3 S...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NKTR	$76.48	+4.13%	899.16K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NKTR	$76.48	+4.1%	899.16K
3
4
5
6

NKTR

NKTR

Get Nektar Therapeutics Data in Excel

Get Nektar Therapeutics Data in Excel